AZX-1101(AZX-1101) - 药物靶点：β-lactamase_专利_临床

概要

基本信息

药物类型

酶

别名

beta lactamases(AzurRx)

靶点

β-lactamase

作用机制

β-lactamase刺激剂(β-内酰胺酶刺激剂)

治疗领域

消化系统疾病感染

在研适应症-

非在研适应症

细菌感染胃肠道疾病

原研机构

AzurRx SAS

在研机构-

非在研机构

Entero Therapeutics, Inc.AzurRx SAS

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 AZX-1101 相关的临床结果

登录后查看更多信息

100 项与 AZX-1101 相关的转化医学

登录后查看更多信息

100 项与 AZX-1101 相关的专利（医药）

登录后查看更多信息

97

项与 AZX-1101 相关的文献（医药）

2024-03-01·Infectious Disease Clinics of North America

Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis

Review

作者: Murray, Thomas S ; Stanley, Gail ; Koff, Jonathan L

Patients with cystic fibrosis (CF) often develop respiratory tract infections with pathogenic multidrug-resistant organisms (MDROs) such as methicillin-resistant Staphylococcus aureus, and a variety of gram-negative organisms that include Pseudomonas aeruginosa, Burkholderia sp., Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and nontuberculous mycobacteria (NTM). Despite the introduction of new therapies to address underlying cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, MDRO infections remain a problem and novel antimicrobial interventions are still needed. Therapeutic approaches include improving the efficacy of existing drugs by adjusting the dose based on differences in CF patient pharmacokinetics/pharmacodynamics, the development of inhaled formulations to reduce systemic adverse events, and the use of newer beta-lactam/beta-lactamase combinations. Alternative innovative therapeutic approaches include the use of gallium and bacteriophages to treat MDRO pulmonary infections including those with extreme antibiotic resistance. However, additional clinical trials are required to determine the optimal dosing and efficacy of these different strategies and to identify patients with CF most likely to benefit from these new treatment options.

2022-12-01·Clinics in Chest Medicine

Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis

Review

作者: Murray, Thomas S ; Koff, Jonathan L ; Stanley, Gail

Patients with cystic fibrosis (CF) often develop respiratory tract infections with pathogenic multidrug-resistant organisms (MDROs) such as methicillin-resistant Staphylococcus aureus, and a variety of gram-negative organisms that include Pseudomonas aeruginosa, Burkholderia sp., Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and nontuberculous mycobacteria (NTM). Despite the introduction of new therapies to address underlying cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, MDRO infections remain a problem and novel antimicrobial interventions are still needed. Therapeutic approaches include improving the efficacy of existing drugs by adjusting the dose based on differences in CF patient pharmacokinetics/pharmacodynamics, the development of inhaled formulations to reduce systemic adverse events, and the use of newer beta-lactam/beta-lactamase combinations. Alternative innovative therapeutic approaches include the use of gallium and bacteriophages to treat MDRO pulmonary infections including those with extreme antibiotic resistance. However, additional clinical trials are required to determine the optimal dosing and efficacy of these different strategies and to identify patients with CF most likely to benefit from these new treatment options.

2022-10-26·Microbiology Spectrum

Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)

Article

作者: García-Castillo, María ; Cercenado, Emilia ; Hernández-García, Marta ; Pitart, Cristina ; Tormo, Nuria ; Pinto, Margarida F. ; Alves, Valquíria ; Duarte, Joana ; Sancho, Luísa ; Pássaro, Leonor ; Chaves, Catarina ; Cruz, Hugo ; Bou, Germán ; Díaz-Regañón, Jazmín ; Diogo, José ; Gonçalves, Elsa ; Oliver, Antonio ; Cantón, Rafael ; Ferreira, Rui ; Rodríguez-Lozano, Jesús ; Vieira, Ana Raquel ; Delgado-Valverde, Mercedes ; Melo-Cristino, José ; Ramalheira, Elmano

We comparatively evaluate the in vitro activity of a drug combination consisting of a carbapenem (imipenem) and a novel inhibitor of beta-lactamases (relebactam), a mechanism that destroys beta-lactam antibiotics. We assess the activity against a collection of Enterobacterales clinical isolates recovered from difficult-to-treat infections in patients admitted to different intensive care units in Portugal and Spain.

100 项与 AZX-1101 相关的药物交易

登录后查看更多信息